ISCHEMIA试验:指南导向药物治疗目标与心血管结局的关系
该研究为ISCHEMIA试验的事后观察性分析,纳入5,179例慢性冠心病患者,评估收缩压<130 mmHg、LDL-C<70 mg/dL、不吸烟及抗血小板治疗四项GDMT目标达成情况与心血管死亡/心肌梗死的关联。结果显示早期达标并维持,尤其收缩压达标,与更少心血管事件相关;基线四项全达标者4年累积事件率最低(8.7%),未达标者最高(24.5%)。
要点
- 慢性冠心病患者早期达成并维持GDMT目标与更少心血管事件相关。
- 收缩压达标与心血管死亡/心肌梗死绝对事件减少显著相关。
- 随访收缩压每降低10 mmHg,心血管死亡/心肌梗死相对风险降低10%。
核心结论
- 在慢性冠心病患者中,早期达成并维持GDMT目标,尤其是收缩压达标,与更少心血管事件相关。
- 与无GDMT目标达标相比,基线四项GDMT目标全部达标与绝对减少16%的心血管死亡和心肌梗死相关。
研究设计与样本
- ISCHEMIA试验的事后观察性研究,纳入全部5,179例慢性冠心病参与者。
- 采用贝叶斯联合模型分析纵向目标状态与至事件时间,评估各GDMT目标达成及达 timing 与心血管死亡/心肌梗死的相对重要性。
主要发现
- 基线四项GDMT目标完整数据的4,914例中,达成0-1、2、3、4项目标者分别为386例(9%)、2,073例(42%)、1,843例(38%)、612例(12%)。
- 4年心血管死亡/心肌梗死累积事件率在未达成任何GDMT目标者中最高(24.5%;95%CrI:13.5%-42.2%),在基线全部达标且随访维持达标者中最低(8.7%;95%CrI:6.7%-10.9%)。
- 收缩压达标与心血管死亡/心肌梗死绝对事件减少显著相关(-5.1%;95%CrI:-11.3%至-1.0%),其次为抗血小板治疗(-11.2%;95%CrI:-29.1%至0.8%)、LDL-C<70 mg/dL(-2.0%;95%CrI:-6.0%至2.4%)和不吸烟(-1.7%;95%CrI:-9.3%至4.2%)。
- 调整其他GDMT目标和基线特征后,随访期间收缩压每降低10 mmHg与心血管死亡/心肌梗死相对风险降低10%相关(RR=0.90;95%CrI:0.82-0.98)。
关键数值与推荐
- GDMT目标包括收缩压<130 mmHg、LDL-C<70 mg/dL、不吸烟和抗血小板治疗。
临床怎么用
- 对慢性冠心病患者应早期评估并促进GDMT四项目标达标,尤其重视收缩压控制至<130 mmHg。
- 随访中维持GDMT目标达标可能进一步降低心血管死亡/心肌梗死风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guideline-directed medical therapy (GDMT) with multiple risk factor goals is recommended for patients with chronic coronary disease (CCD), yet achieving all GDMT goals is uncommon. The relative importance of these goals and timing of their attainment on cardiovascular events is uncertain. OBJECTIVES: This study aims to describe the relationship between achieving specific GDMT goals, when they are achieved, and clinical outcomes. METHODS: This was an observational study of participants with CCD in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. The primary outcome was cardiovascular (CV) death or myocardial infarction (MI). GDMT goals were systolic blood pressure (SBP) <130 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, not smoking, and antiplatelet therapy. Frequency of GDMT goals met at baseline and during follow-up is described. Bayesian joint modeling for longitudinal goal status and time-to-event analyses characterized the relative importance of specific GDMT goal attainment and timing with CV death/MI. RESULTS: All 5,179 ISCHEMIA participants were included. Among 4,914 participants with complete data on all 4 GDMT goals at baseline, 386 (9%), 2,073 (42%), 1,843 (38%), and 612 (12%) met 0-1, 2, 3, and 4 GDMT goals, respectively. The 4-year cumulative event rate for CV death/MI was highest for participants who attained no GDMT goals (24.5%; 95% credible interval [CrI]: 13.5%-42.2%) and lowest for those who attained all goals at baseline and remained at goal during follow-up (8.7%; 95% CrI: 6.7%-10.9%). SBP goal attainment was associated with a significant absolute event reduction in CV death/MI (-5.1%; 95% CrI: -11.3% to -1.0%), followed by antiplatelet therapy (-11.2%; 95% CrI: -29.1% to 0.8%), achieving low-density lipoprotein cholesterol <70 mg/dL (-2.0%; 95% CrI: -6.0% to 2.4%), and not smoking (-1.7%; 95% CrI: -9.3% to 4.2%). Ten millimeters of mercury lower SBP during follow-up was associated with 10% relative risk reduction of CV death/MI (RR [relative risk] = 0.90; 95% CrI: 0.82-0.98), after adjusting for other GDMT goals and baseline characteristics. CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).
引用
- Maron DJ, Newman JD, Anthopolos R, et al. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2025. PMID: 40139888. doi:10.1016/j.jacc.2025.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。